Phospho-CDK6 (Tyr24) Antibody
Shipped with Ice Packs 
In Stock 
Product Specs
Form
Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
Typically, we can ship your orders within 1-3 business days after receiving them. The delivery timeframe may vary based on the purchasing method and location. For specific delivery details, please consult your local distributors.
Synonyms
CDK 6 antibody; CDK6 antibody; CDK6_HUMAN antibody; Cell division protein kinase 6 antibody; Crk 2 antibody; Crk2 antibody; Cyclin dependent kinase 6 antibody; Cyclin-dependent kinase 6 antibody; MCPH12 antibody; MGC59692 antibody; p40 antibody; PLSTIRE antibody; Serine/threonine protein kinase PLSTIRE antibody; Serine/threonine-protein kinase PLSTIRE antibody; STQTL11 antibody
Target Names
Uniprot No.
Target Background
Function
Cyclin-dependent kinase 6 (CDK6) is a serine/threonine-protein kinase that plays a pivotal role in regulating cell cycle progression and differentiation. Notably, CDK6 promotes the transition from the G1 to S phase of the cell cycle. This function is mediated by its phosphorylation of key proteins like pRB/RB1 and NPM1. During interphase, CDK6 interacts with D-type G1 cyclins, forming a complex that acts as a pRB/RB1 kinase. This complex controls entry into the cell cycle. CDK6 also contributes to cell cycle exit during differentiation, preventing uncontrolled proliferation and negatively regulating differentiation. However, CDK6 is essential for the proliferation of specific cell types, such as erythroid and hematopoietic cells. Furthermore, CDK6 is crucial for cell proliferation within the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles, indicating its role in neurogenesis. CDK6 is also required during thymocyte development. In addition to its role in cell cycle regulation, CDK6 contributes to the production of newborn neurons, likely by modulating G1 length. Interestingly, in astrocytes, CDK6 promotes changes in gene expression patterns, alterations in the actin cytoskeleton (including the loss of stress fibers), and enhanced motility during differentiation. CDK6 also exhibits an inhibitory effect on myeloid differentiation by interfering with RUNX1 and reducing its transcriptional transactivation activity. Conversely, it promotes the proliferation of normal myeloid progenitors. Moreover, CDK6 delays senescence and promotes the proliferation of beta-cells in pancreatic islets of Langerhans. Lastly, CDK6 may play a role in centrosome organization during the cell cycle phases.
Gene References Into Functions
- Inhibition of CDK6 and overexpression of MiR-320c attenuated IL-1beta-induced increases in the expression of inflammatory products, such as iNOS and MMP13, and decreased the expression of anabolic products, such as COL2A1 and aggrecan. PMID: 30466085
- Our findings suggest that miR-29a plays a significant role in inhibiting proliferation and motility of cancerous Schwann cells and may suppress tumor growth through upregulation of CDK6. PMID: 29023945
- High CDK6 expression is associated with Oral Squamous Cell Carcinomas. PMID: 29693970
- These results indicate that C-glycosyl flavone may induce apoptosis, cell cycle arrest, and inhibit angiogenesis via CDK6. Targeting CDK6 using C-glycosyl flavone may serve as a novel therapeutic approach for treating breast, hepatic, and colon cancers. PMID: 29806604
- The miR494/CDK6 axis exhibits a significant tumor-suppressive effect on osteosarcoma. PMID: 28990071
- High CDK6 expression is associated with bladder carcinoma. PMID: 27484176
- Molecular dynamics simulations revealed that the free energy barrier for the transition from the open to closed state decreased approximately 47.2% after Thr177 phosphorylation, increasing the flexibility around the ATP-binding pocket. Binding preferences of 10 different inhibitors to the open or closed state were also investigated. PMID: 29108955
- miRNA-195 was associated with tumor malignancy grade and might be involved in the development and progression of Ovarian Cancer (OVC). Furthermore, CDK6, a predicted target gene of miRNA-195, was noticeably increased in both OVC and Oral Squamous Cell Carcinoma (OSCC). PMID: 28621315
- Results show that miR-218-5p is increased in bone metastases and promotes breast cancer cell proliferation by activating Wnt signaling. PMID: 27738322
- Upregulation of CDK6 may serve as an important mechanism for overcoming fulvestrant-mediated growth inhibition in breast cancer cells. PMID: 27252418
- The MYU/hnRNP-K/CDK6 pathway functions downstream of Wnt/c-Myc signaling and plays a critical role in the proliferation and tumorigenicity of colon cancer cells. PMID: 27568568
- The deletion of CBX3 directly promotes the expression of CDK6 and p21. PMID: 28193906
- CDK6-mediated suppression of CD25 is required for the initiation of T-cell acute lymphoblastic leukemia (T-ALL) by activated Notch1. PMID: 26707936
- CDK6 overexpression is associated with cancer. PMID: 27206849
- High CDK6 expression is associated with Melanoma. PMID: 26988987
- Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein. PMID: 28168755
- Our study confirmed that the CDK6 gene is a target of miR-637 and demonstrated the regulatory association between miR-637 and CDK6. PMID: 27794186
- miR-1299 inhibited CDK6 expression and bound to the 3'UTR of CDK6. PMID: 27490780
- Results show that NEAT1 regulates CDK6 expression in laryngeal squamous cell cancer (LSCC) cells, which was mediated by miR-107. NEAT1 plays an oncogenic role in the tumorigenesis of LSCC. PMID: 26822763
- Lower expression in cisplatin-resistant non-small-cell lung carcinoma. PMID: 25703099
- Three uniquely identified proteins (CDK6, galectin-3-binding protein, and LDH C) were found, showing a strong connection with prostate cancer. The presence of all these proteins has previously been linked to certain aspects of prostate cancer. PMID: 26503549
- These data enhance our understanding of the important role that GAS5 plays in the molecular etiology of Gastric Cancer (GC) and suggest a potential for GAS5 as a new therapeutic target for GC treatment. PMID: 26278580
- MiR-26a and miR-584 inhibit the binding of hnRNP A1-CDK6 mRNA and induce colorectal cancer cell apoptosis. PMID: 26494299
- Only miR-34a was prognostic for Recurrence-Free Survival (RFS) (RR, 11.5; P = 0.027). miR-34a expression was inversely correlated with that of c-MET and CDK6 in non-small cell lung cancer, and had prognostic significance for RFS, particularly in adenocarcinoma patients. PMID: 26104764
- We conclude that Bortezomib (Bz)-surviving Multiple Myeloma (MM) cells display a GRP78(HIGH)/p21(HIGH)/CDK6(LOW)/P-Rb(LOW) profile, and these markers may identify quiescent MM cells capable of fueling recurrences. PMID: 26025442
- Differential expression of CDK6 underlies heterogeneity in stem cell quiescence states that functionally regulates this highly regenerative system. PMID: 25704240
- LINE-1 hypomethylation was associated with higher cancer recurrence, and CDK6 messenger RNA expression levels were inversely associated with LINE-1 methylation in hepatocellular carcinomas. PMID: 25319577
- miR-320c could inhibit the proliferation, migration, and invasion of bladder cancer cells via regulating CDK6. PMID: 25178497
- SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. PMID: 24953629
- Cooperation of Deleted in Liver Cancer 1 (DLC1) and CDK6 affects breast cancer clinical outcome. PMID: 25425654
- Our data suggest that miR-377 can suppress proliferation in MG-63 cells, partly by targeting CDK6. PMID: 25577249
- Genetic variants in CDK6 and Peptidylarginine Deiminase 4 (PADI4) were associated with anti-citrullinated cyclic peptide status in rheumatoid arthritis DRB1*04 negative patients. PMID: 25138370
- CDK6 is a direct target of Mixed Lineage Leukemia (MLL) fusion proteins, playing an important role in the proliferation advantage of MLL-rearranged Acute Lymphoblastic Leukemia (ALL) cells. PMID: 24736461
- The addition of CDK4/6 inhibitor palbociclib to letrozole in this phase 2 study significantly improved progression-free survival in women with advanced estrogen receptor-positive and HER2-negative breast cancer. PMID: 25524798
- Results suggest that DCK6 is a putative target of miR504 in hypopharyngeal squamous cell carcinoma. PMID: 24647829
- Cases with CDK6-positive expression experienced worse clinical outcomes compared with those with CDK6-negative expression, supporting the oncogenic role of CDK6 in Esophageal Squamous Cell Carcinoma (ESCC). PMID: 24423610
- These findings identify a direct relationship between control of the cell cycle by CDK6 and SAMHD1 activity, which is essential for the replication of lentiviruses, as well as other viruses whose replication may be regulated by intracellular dNTP availability. PMID: 25015816
- Findings begin to elucidate the role of miR-145 as an important regulator of chemoresistance in ovarian cancer by controlling both Cdk6 and Sp1. PMID: 24510775
- Overexpression of hsa-miR-4516 downregulates STAT3, p-STAT3, CDK6, and UBE2N proteins, which are consistently upregulated in psoriasis and induces apoptosis in HaCaT cells. PMID: 24610393
- An evolving tumor can only derive full benefit from overexpression of CDK6 in the absence of P16INK4A. PMID: 24161991
- MYC-dependent breast cancer cells possess high MYC expression and high levels of MYC phosphorylation but are not sensitive to inhibition of CDK6. PMID: 24444383
- This interaction suggests that CDK6 regulates Eyes Absent 2 (EYA2) activity, a mechanism that could be essential in development and in cancer. PMID: 24196439
- Growth arrest-specific 5 (Gas5) negatively regulates CDK6 expression in vitro and in vivo in pancreatic cancer cells. PMID: 24026436
- Data identify CDK6 as a critical effector of MLL fusions in leukemogenesis, which might be targeted to overcome the differentiation block associated with MLL-rearranged acute myeloid leukemia. PMID: 24764564
- Data indicate CDK6 as a putative target of miR-105, which is likely a main contributor to the inhibition of tumor cell growth observed in our assays. PMID: 23950948
- CDK6 rs42041 was associated with a remitting course of juvenile idiopathic arthritis. PMID: 24347572
- We propose that the identified CDK6 mutation leads to reduced cell proliferation and impairs the correct functioning of the centrosome in microtubule organization and its positioning near the nucleus, which are key determinants during neurogenesis. PMID: 23918663
- Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PMID: 24069260
- Results showed that let-7a acted as a tumor suppressor in Ewing Sarcoma (ES) by targeting CDK6. This finding may provide novel diagnostic and therapeutic options for human Ewing sarcoma clinical management in the future. PMID: 24383407
- CDK6 was identified as a novel functional target of miR200a. Our data indicate that miR200a functions as a potential tumor suppressor in Hepatocellular Carcinoma (HCC). PMID: 24009066
Database Links
Involvement In Disease
Microcephaly 12, primary, autosomal recessive (MCPH12)
Protein Families
Protein kinase superfamily, CMGC Ser/Thr protein kinase family, CDC2/CDKX subfamily
Subcellular Location
Cytoplasm. Nucleus. Cell projection, ruffle. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.
Tissue Specificity
Expressed ubiquitously. Accumulates in squamous cell carcinomas, proliferating hematopoietic progenitor cells, beta-cells of pancreatic islets of Langerhans, and neuroblastomas. Reduced levels in differentiating cells.
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
